Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof

US9023318B2 · kind B2 · utility

Assignee

• Siemens Medical Solutions USA, Inc. · US

Inventors

• Gang Chen · Sammamish, US
• Umesh B. Gangadharmath · Los Angeles, US
• Dhanalakshmi Kasi · Los Angeles, US
• Harmuth C. Kolb · Chino, US
• Changhui Liu · Los Angeles, US
• Anjana Sinha · San Diego, US
• Anna Katrin Szardenings · San Diego, US
• Joseph C. Walsh · Santa Monica, US
• Eric Wang · Yonkers, US
• Chul Yu · Los Angeles, US
• Wei Zhang · San Diego, US
• Klaus Kopka · Dossenheim, DE
• Guenter Haufe · Munster, DE
• Michael Schaefers · Munster, DE
• Verena Hugenberg · Bersenbrück, DE
• Stefan Wagner · Munster, DE
• Sven Hermann · Munster, DE
• Hans-Joerg Breyholz · Munster, DE
• Andreas Faust · Billerbeck, DE

Key dates

• Filing date: Mar 25, 2013
• Grant date: May 5, 2015
• Expiry date: Jun 18, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.